ライフサイエンスコーパス: mitral valve repair

1 transcatheter valve therapies (for example, mitral valve repair).

2 the mitral valve leaflets (eg, transcatheter mitral valve repair).

3 st- atrial fibrillation ablation or surgical mitral valve repair).

4 orable clinical response after transcatheter mitral valve repair.

5 is relatively normal in patients undergoing mitral valve repair.

6 ts who are being evaluated for transcatheter mitral valve repair.

7 valve replacement (MVR) may be favored over mitral valve repair.

8 t alone or coronary artery bypass graft with mitral valve repair.

9 n particular, mechanical cardiac support and mitral valve repair.

10 e as well as the improved outcome related to mitral valve repair.

11 cardiologist can result in increased rate of mitral valve repair.

12 ecting percutaneous treatment strategies for mitral valve repair.

13 of a percutaneous catheter-based system for mitral valve repair.

14 roup consisted of 6 patients who had primary mitral valve repair.

15 l annular papillary muscle continuity during mitral valve repair.

16 ler imaging in patients with hemolysis after mitral valve repair.

17 nvolved in the occurrence of hemolysis after mitral valve repair.

18 d right minithoracotomy procedure (Mini) for mitral valve repair.

19 all cases and 0.21% (5 of 2,399) in isolated mitral valve repair.

20 ter edge-to-edge repair relative to surgical mitral valve repair.

21 x artery occlusion during minimally invasive mitral valve repair.

22 nt limitations associated with transcatheter mitral valve repair.

23 height >/=5 mm) and 5 others (8%) underwent mitral valve repair.

24 egurgitation, the most common indication for mitral valve repair.

25 ients with severe MR even after percutaneous mitral valve repair.

26 scharge, 30 days, 6 months, and 1 year after mitral valve repair.

27 uld be considered an alternative to surgical mitral valve repair.

28 oved LV ejection fraction after percutaneous mitral valve repair.

29 chanical energy (pressure-volume area) after mitral valve repair.

30 approach should be routinely used in complex mitral valve repairs.

31 % in the CABG-alone group (hazard ratio with mitral-valve repair, 0.90; 95% confidence interval, 0.38

32 52 robotic-assisted clinical operations: 18 mitral valve repairs, 20 cholecystectomies, and 14 Nisse

33 re 28 degrees C) without aortic cross-clamp, mitral valve repair (224/504, 44%) or replacement (280/5

34 ns predicted risk of mortality with surgical mitral valve repair, 4.6%).

35 luded coronary artery bypass grafting (13%), mitral valve repair (7%), and partial/complete arch repl

36 T2 inhibitors, vericiguat, and transcatheter mitral valve repair, all of which incrementally improve

37 Survival after mitral valve repair among elderly patients is equivalent

38 undergoing mitral valve surgery, especially mitral valve repair, an approach of earlier identificati

39 able a complete operation that includes both mitral valve repair and ablation of atrial fibrillation.

40 , 0.92 and 0.97 for pacemakers, percutaneous mitral valve repair and artificial aortic valves, respec

41 ) and severe mitral regurgitation undergoing mitral valve repair and coronary artery bypass graft ope

42 To review the evolution of mitral valve repair and outline currently favored repair

43 asive aortic (n = 41) and minimally invasive mitral valve repair and replacement (n = 43) between Jul

44 st decade and become the preferred method of mitral valve repair and replacement at certain specializ

45 are fee-for-service beneficiaries undergoing mitral valve repair and replacement over a 10-year perio

46 guiding surgical and percutaneous methods of mitral valve repair and replacement.

47 l per square meter of body-surface area with mitral-valve repair and 60.6+/-39.0 ml per square meter

48 igned in a 1:1 ratio to either transcatheter mitral-valve repair and guideline-recommended medical th

49 at 12 months between patients who underwent mitral-valve repair and those who underwent mitral-valve

50 al regurgitation (MR) following degenerative mitral valve repair are poorly understood.

51 Flexible annuloplasty devices used in mitral valve repair are, therefore, unlikely to result i

52 Mitral valve repair as a proportion of all mitral valve

53 Mitral valve repair avoids the complications associated

54 rent practice for mitral valve surgery, with mitral valve repair being the technique of choice.

55 underwent transfemoral TAVR or transcatheter mitral valve repair between 2011 and 2018 (mean age, 81.

56 g reoperation for mitral regurgitation after mitral valve repair but without hemolysis served as cont

57 , cardiac resynchronization or transcatheter mitral valve repair), but they may derive little benefit

58 to evaluate renal function before and after mitral valve repair by the MitraClip device.

59 Percutaneous edge-to-edge mitral valve repair can be performed safely and a reduct

60 Percutaneous mitral valve repair can serve as an alternative for surg

61 veral groups have now confirmed that complex mitral valve repairs can be carried out robotically with

62 Mitral-valve repair can be accomplished with an investig

63 tients in atrial fibrillation (AF) following mitral valve repair, clinical and echocardiographic foll

64 ral regurgitation to CABG alone or CABG plus mitral-valve repair (combined procedure).

65 In severe MR due to MVP, mitral valve repair compared with MVR provides improved

66 w likelihood of MR recurrence, regardless of mitral valve repair complexity.

67 dge-to-edge technique using the percutaneous mitral valve repair device in an ex vivo pulsatile model

68 commercially treated with this percutaneous mitral valve repair device were analyzed.

69 gurgitation undergoing CABG, the addition of mitral-valve repair did not lead to significant differen

70 Whether mitral valve repair during coronary artery bypass grafti

71 of the mitral valve apparatus from extensive mitral valve repair experience.

72 n the outcomes of transcatheter edge-to-edge mitral valve repair for degenerative mitral regurgitatio

73 After mitral valve repair for degenerative mitral regurgitatio

74 gradients can develop in some patients after mitral valve repair for degenerative mitral regurgitatio

75 Consecutive patients who underwent isolated mitral valve repair for degenerative MR at a single inst

76 stry who underwent nonemergent transcatheter mitral valve repair for degenerative MR in the US from 2

77 Mitral valve repair for mitral regurgitation (MR) has be

78 inical results of a percutaneous approach to mitral valve repair for mitral regurgitation (MR).

79 etween 1991 and 2010, patients who underwent mitral valve repair for primary mitral regurgitation wer

80 After mitral valve repair for primary mitral regurgitation, th

81 h a mean (SD) age of 57 (11) years underwent mitral valve repair for regurgitation from posterior lea

82 98.8% complete follow-up) underwent robotic mitral valve repair for severe nonischemic degenerative

83 the commercial experience with transcatheter mitral valve repair for the treatment of mitral regurgit

84 e-sixth of patients undergoing transcatheter mitral valve repair had AKI, linked to device failure or

85 Although mitral valve repair has become recently popularized for

86 Mitral valve repair has become the mainstay of surgical

87 The success of the mitral valve repair has led to increased scrutiny of mit

88 ound the time of both TAVR and transcatheter mitral valve repair has not been fully defined.

89 In the current era, mitral valve repair has proven to offer improved short-t

90 Mitral valve repair has reduced LOS and improved in-hosp

91 tic aneurysm repair, carotid endarterectomy, mitral valve repair, hip or knee replacement, bariatric

92 Percutaneous mitral valve repair improves hemodynamic profiles and in

93 Whether transcatheter mitral-valve repair improves outcomes in patients with h

94 uded coronary artery bypass grafting in 95%, mitral valve repair in 22%, and mitral valve replacement

95 Operations performed included mitral valve repair in 27 patients; mitral valve replace

96 t in 9; coronary artery bypass surgery in 3; mitral valve repair in 2; and septal myectomy, mitral va

97 predict postoperative LVD and outcome after mitral valve repair in patients with primary mitral regu

98 interventricular dyssynchrony, transcatheter mitral valve repair in patients with severe secondary mi

99 In addition, concomitant mitral valve repair in these patients resulted in a bett

100 was to assess long-term mortality following mitral valve repair in women compared with men on the ba

101 bypass grafting (CABG) alone with CABG plus mitral-valve repair in patients with moderate ischemic m

102 Percutaneous mitral valve repair increased end-systolic wall stress (

103 The rates of mitral valve repair increased from 47.7% in the lowest-v

104 ring transapical neochordae implantation for mitral valve repair, increasing accuracy and reproducibi

105 We screened 275 patients who had mitral valve repair involving >1 leaflet scallop between

106 In expert centers, mitral valve repair is achieved at low risk and with exc

107 In addition, transcatheter mitral valve repair is also routinely used in high surgi

108 Performance of AVR and concomitant mitral valve repair is associated with a better survival

109 ted that recurrent MR following degenerative mitral valve repair is associated with adverse left vent

110 ore and 30 days after TAVR and transcatheter mitral valve repair is associated with subsequent risk o

111 elderly patients with mitral regurgitation, mitral valve repair is associated with superior early an

112 Mitral valve repair is being explored, with surprisingly

113 gs demonstrate that commercial transcatheter mitral valve repair is being performed in the United Sta

114 Mitral valve repair is currently applied to close to 60%

115 Still, mitral valve repair is far more complex than mitral valv

116 Mitral valve repair is favoured over replacement wheneve

117 Mitral valve repair is superior to replacement.

118 at highest risk for complications, and that mitral valve repair is the treatment of choice for sympt

119 dical therapy, the addition of transcatheter mitral-valve repair led to a lower rate of first or recu

120 ke volume and perfusion of the LV apex after mitral valve repair may facilitate thrombus formation es

121 MITRA-FR (Multicentre Study of Percutaneous Mitral Valve Repair MitraClip Device in Patients with Se

122 lar trial, Multicenter Study of Percutaneous Mitral Valve Repair MitraClip Device in Patients With Se

123 >65 years of age who underwent transcatheter mitral valve repair (MitraClip) for severe mitral regurg

124 nsecutively operated for MR (procedures: 897 mitral valve repair [MRep] and 447 valve replacement: 23

125 The role of mitral valve repair (MVR) during coronary artery bypass

126 Tricuspid valve annuloplasty (TA) during mitral valve repair (MVr) is associated with increased r

127 e-to-edge repair (TEER) on national surgical mitral valve repair (MVr) volume and outcomes is unknown

128 placement (MVR), 10.5% (n = 8,219) underwent mitral valve repair (MVr), 5.4% (n = 4,202) underwent AV

129 the understanding of changes occurring after mitral valve repair (MVR).

130 o underwent successful revascularization and mitral valve repair (MVRep) for functional ischemic mitr

131 LV thrombus formation following percutaneous mitral valve repair occurred exclusively in patients wit

132 her 30-day mortality for 2 of 10 procedures (mitral valve repair: odds ratio [OR], 1.11; 95% CI, 1.07

133 In the absence of level one evidence, mitral valve repair offers an effective and durable surg

134 ural costs, robotically assisted surgery for mitral valve repair offers the clinical benefit of least

135 Open mitral valve repair (OMVP) is hypothesized to improve sy

136 ic valve replacement (TAVR) or transcatheter mitral valve repair on patients' symptoms, function, and

137 s from 2015 to 2018: carotid endarterectomy, mitral valve repair, open aortic aneurysm repair, lung r

138 Ten sheep underwent 3 randomized, paired mitral valve repair operations: neochord repair, nonrese

139 This study provided key insights about mitral valve repair optimization and may further improve

140 tients with mitral valve prolapse undergoing mitral valve repair or from organ donors without mitral

141 who required subsequent surgery had elective mitral valve repair or intended replacement.

142 for recurrent rheumatic attacks, the use of mitral valve repair or reconstruction for rheumatic mitr

143 nterval, 0.51-0.62; P<0.0001), and CABG plus mitral valve repair or replacement (adjusted hazard rati

144 ted conservatively and those having surgical mitral valve repair or replacement (SMVR) or percutaneou

145 D TEE to evaluate mitral regurgitation after mitral valve repair or replacement as a result of mitral

146 g therapies may alleviate symptoms, but only mitral valve repair or replacement can provide significa

147 =65 years of age undergoing primary isolated mitral valve repair or replacement from 2000 to 2009.

148 In these cases, concomitant mitral valve repair or replacement is usually performed

149 Surgical mitral valve repair or replacement was performed earlier

150 Guideline-directed medical therapy, surgical mitral valve repair or replacement, and, in the setting

151 ace subgroups, and among patients undergoing mitral valve repair or replacement, but remained higher

152 proaches include coronary revascularization, mitral valve repair or replacement, cardiomyoplasty, lef

153 revascularization in combination with either mitral valve repair or replacement.

154 ients were withdrawn after randomization for mitral valve repair or replacement.

155 artery bypass grafting (CABG), or CABG plus mitral valve repair or replacement.

156 dy of 612 consecutive patients who underwent mitral valve repair or replacement: 226 patients had rep

157 ry intervention=26%, CABG=33%, and CABG plus mitral valve repair or replacement=5%.

158 hemic mitral regurgitation to undergo either mitral-valve repair or chordal-sparing replacement in or

159 edge repair (intervention group) or surgical mitral-valve repair or replacement (surgery group).

160 In patients undergoing mitral-valve repair or replacement for severe ischemic m

161 We randomly assigned 251 patients to mitral-valve repair or replacement.

162 ein (OR 1.42, 95% CI 1.21-1.67, p < 0.0001), mitral valve repair (OR 2.86, 95% CI 1.72-4.73, p < 0.00

163 MR include surgical revascularization alone, mitral valve repair, or MVR.

164 Transcatheter mitral valve repair, particularly edge-to-edge leaflet r

165 Thirty-five patients underwent mitral valve repair per current guideline recommendation

166 receive either minithoracotomy or sternotomy mitral valve repair performed by an expert surgeon.

167 ty ring or band implantation during surgical mitral valve repair perturbs mitral annular dimensions,

168 repair or replacement (SMVR) or percutaneous mitral valve repair (PMVR) using edge-to-edge repair.

169 effects in patients undergoing percutaneous mitral valve repair (PMVR) using the edge-to-edge techni

170 (Comparing the Effectiveness of a Mitral Valve Repair Procedure in Combination With Corona

171 Mitral-valve repair provided a more durable correction o

172 uence of surgeon case volume on degenerative mitral valve repair rates and outcomes.

173 nnual mitral volumes of >50 and degenerative mitral valve repair rates of >70%, compared with surgeon

174 Degenerative mitral valve repair rates remain highly variable, despit

175 en aortic aneurysm repair, knee replacement, mitral valve repair, rectal resection, and carotid endar

176 ic valve implantation systems, transcatheter mitral valve repair/replacement systems, surgical aortic

177 The minimally invasive approach for complex mitral valve repair requires continued development and i

178 If untreated at the time of surgical mitral valve repair, significant residual TR negatively

179 Surgical mitral valve repair (SMVR) remains the gold standard for

180 In the hands of reference mitral valve-repair surgeons, 95-100% of degenerative va

181 ly expand the range of patients suitable for mitral valve repair surgery and give further evidence to

182 e interstitial cells (MVICs) obtained during mitral valve repair surgery of a proband.

183 degenerative mitral regurgitation undergoing mitral valve repair surgery.

184 itral regurgitation (MR) were treated with a mitral valve repair system (MVRS) via small left thoraco

185 (Pivotal Study of a Percutaneous Mitral Valve Repair System [EVEREST II]; NCT00209274).

186 000 TAVI procedures and 10 000 transcatheter mitral valve repairs take place yearly in the US to trea

187 Increasing use of mitral valve repair techniques resulted in a marked decr

188 The increased use of mitral valve repair techniques to address mitral valve d

189 tratification for transcatheter edge-to-edge mitral valve repair (TEER) is paramount in the decision-

190 losure (LAAO) and transcatheter edge-to-edge mitral valve repair (TEER) require an interventional ech

191 ith degenerative MR undergoing transcatheter mitral valve repair, the procedure was safe and resulted

192 Transcatheter mitral valve repair (TMVr) for the treatment of mitral r

193 The use of transcatheter mitral valve repair (TMVR) has gained widespread accepta

194 tension influences outcomes of transcatheter mitral valve repair (TMVr) in patients with HF with SMR.

195 However, the results with transcatheter mitral valve repair (TMVR) in prohibitive-risk DMR patie

196 Transcatheter mitral valve repair (TMVR) is a treatment option in pati

197 l Mitral Regurgitation) trial, transcatheter mitral valve repair (TMVr) led to reduced heart failure

198 th severe MR and the impact of transcatheter mitral valve repair (TMVr) on new-onset ESRD and the nee

199 Transcatheter mitral valve repair (TMVr) plus maximally tolerated guid

200 e devices currently available, transcatheter mitral valve repair (TMVr) remains challenging in comple

201 l Mitral Regurgitation) trial, transcatheter mitral valve repair (TMVr) resulted in fewer heart failu

202 itation, patients treated with transcatheter mitral valve repair (TMVr) through leaflet approximation

203 dary mitral regurgitation with transcatheter mitral valve repair (TMVr) using the MitraClip plus guid

204 rated health status benefit of transcatheter mitral valve repair (TMVr) with MitraClip in patients wi

205 l Mitral Regurgitation) trial, transcatheter mitral valve repair (TMVr) with the MitraClip rapidly im

206 ary mitral regurgitation (MR), transcatheter mitral valve repair (TMVr) with the MitraClip reduced MR

207 demonstrated that edge-to-edge transcatheter mitral valve repair (TMVr) with the MitraClip resulted i

208 these observational data suggest that adding mitral valve repair to CABG in patients with left ventri

209 Robotic technology now allows complex mitral valve repairs to be carried out via small incisio

210 chemic mitral regurgitation, the addition of mitral-valve repair to CABG did not result in a higher d

211 a clinically meaningful advantage of adding mitral-valve repair to CABG.

212 derate regurgitation, the benefits of adding mitral-valve repair to coronary-artery bypass grafting (

213 me in which patients underwent transcatheter mitral valve repair using the Edwards PASCAL TMVr system

214 rea (MVA) is important to guide percutaneous mitral valve repair using the MitraClip system.

215 tery bypass graft, aortic valve replacement, mitral valve repair) using an interrupted time series mo

216 ted in pregnancy than valvular stenosis, but mitral valve repair, usually feasible for nonrheumatic p

217 fit-risk tradeoffs relevant to transcatheter mitral valve repair versus medical therapy for patients

218 e risk adjustment was modified to adjust for mitral valve repair versus replacement.

219 ), and the proportion of patients undergoing mitral valve repair (versus replacement) increased (24.7

220 The safety and effectiveness of mitral valve repair via thoracoscopically-guided minitho

221 cic Surgeons predicted risk of mortality for mitral valve repair was 4.8% (2.1-9.0) and 6.8% (2.9-10.

222 The addition of mitral-valve repair was associated with a longer bypass

223 Concomitant mitral-valve repair was associated with a reduced preval

224 Mitral-valve repair was associated with a reduced preval

225 degenerative MR who underwent transcatheter mitral valve repair were analyzed (median age, 82 years;

226 ents commercially treated with transcatheter mitral valve repair were analyzed.

227 Effect of AVR and concomitant mitral valve repair were investigated.

228 <=60%), with a class IIA recommendation for mitral valve repair when performed at an experienced sur

229 ecutive patients with hemolytic anemia after mitral valve repair who were referred for mitral reopera

230 o timely curative therapies such as surgical mitral valve repair will improve the outcomes of many in

231 Transcatheter mitral valve repair with a MitraClip device is also prod

232 Mitral valve repair with annuloplasty has become a widel

233 Mitral valve repair with annuloplasty has become a widel

234 l regurgitation (MR) has been reported after mitral valve repair with annuloplasty in patients with d

235 Transcatheter edge-to-edge mitral valve repair with the MitraClip device (Abbott).

236 Percutaneous mitral valve repair with the MitraClip device has emerge

237 ry determination who underwent transcatheter mitral valve repair with the MitraClip device in multice

238 Transcatheter mitral valve repair with the MitraClip in patients with

239 Transcatheter mitral valve repair with the MitraClip results in marked

240 eld has resulted in approval of edge-to-edge mitral valve repair with the MitraClip, and there are se

241 In a randomized trial comparing mitral-valve repair with mitral-valve replacement in pat

242 y that enables a double-orifice edge-to-edge mitral valve repair without cardiopulmonary bypass in an

243 After mitral valve repair, women have a higher risk for all-ca